A practical reference on Regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-11 and is reviewed periodically as new material appears.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
However, most glucose does not occur in its free form, but in the form of its polymers (polysaccharides), such as sucrose and starch commonly found in plants, lactose in milk, cellulose from plant cell wall, and chitin from arthropods. These polymers, when consumed by animals, fungi, and bacteria, are degraded to glucose using enzymes. All animals are also able to produce glucose themselves from certain precursors as the need arises. Neurons, cells of the renal medulla, and erythrocytes depend on glucose for their energy production. In adult humans, there is about 18 g (0.63 oz) of glucose, of which about 4 g (0.14 oz) is present in the blood. Approximately 180–220 g (6.3–7.8 oz) of glucose is produced in the liver of an adult in 24 hours. Many of the long-term complications of diabetes (e.g., blindness, kidney failure, and peripheral neuropathy) are probably due to the glycation of proteins or lipids. In contrast, enzyme-regulated addition of sugars to protein is called glycosylation and is essential for the function of many proteins.
Creatinine levels in μmol/L can be converted to mg/dL by dividing them by 88.4. The 32788 number above is equal to 186×88.41.154. A more elaborate version of the MDRD equation also includes serum albumin and blood urea nitrogen (BUN) levels:
=== Missing and identification === According to UNICEF, the standard system for identifying, documenting, tracing and reuniting children with relatives or siblings was barely functional in early December 2023. Additional difficulties arose from the intensity of the fighting and the rapidly changing conditions in Gaza, which hindered efforts to communicate with hospitals and medical staff. Four months into the conflict, the UN estimated that about 40% of all people in Gaza had lost identification cards and documents due to the war, making it more difficult to identify unaccompanied children and reunite them with their families. Humanitarian organizations also reported difficulties with orphaned children who were too young to know their own names. A UNICEF spokesman said: "The youngest ones very often cannot say their name and even the older ones are usually in shock so it can be extremely difficult to identify them". Hospital and emergency workers in Gaza noted that parents and relatives of some children wrote on children's bodies, mostly on their legs and abdomens, so the children would be identifiable if found in the rubble or get lost. One employee stated: "Many of the children are missing, many get here with their skulls broken… and it’s impossible to identify them, only through that writing do they get identified." In June 2024, Save the Children stated approximately 21,000 children were missing in Gaza, including 4,000 children believed to be buried under rubble. The bodies of some of these children remained unrecovered.
Sources: en.wikipedia.org
During February 1945, the 4th Panzer Army defended along the Oder River, containing the Soviet bridgehead at Steinau on the Oder. In March and the first half of April 1945, the army concentrated on defenses along the Lusatian Neisse River between Görlitz and Guben. On April 16, 1945, the Red Army renewed its offensive by crossing the Oder River. While the 9th Army held the Soviet forces at the Battle of Seelow Heights, the 4th Panzer Army was being pushed back. V Corps of the retreating 4th Panzer Army was pushed into the operational region of the German 9th Army, forming a pocket of some 80,000 men. The Red Army then encircled this force in a pocket in the Spree Forest south of the Seelow Heights and west of Frankfurt. Some of the 4th Panzer Army troops trapped in the Halbe Pocket broke out to the west and surrendered to the US Army on the west bank of the Elbe River. The bulk of the 4th Panzer Army was pushed south of Dresden into the Ore Mountains where it surrendered to the Red Army in the wake of the early May 1945 Prague Offensive.
An investigation scrutinizing gingerol's anti-fungal capabilities remarked that an African species of ginger tested higher in both gingerol and shogaol compounds than the more commonly cultivated Indonesian relative. When tested for the anti-fungal properties the African ginger combated against 13 human pathogens and was three times more effective than the commercial Indonesian counterpart. It is thought that gingerol compounds work in tandem with the other phytochemicals present including shogaols, paradols and zingerone.
The National Commission on Terrorist Attacks Upon the United States, popularly known as the 9/11 Commission, chaired by Thomas Kean, was formed in late 2002 to prepare a thorough account of the circumstances surrounding the attacks, including preparedness for and the immediate response to the attacks. The commission issued the 9/11 Commission Report in July 2004, a 585-page report based on its investigations. The report detailed the events leading up to the attacks, concluding that they were carried out by al-Qaeda. The commission also examined how security and intelligence agencies were inadequately coordinated to prevent the attacks. According to the report, "We believe the 9/11 attacks revealed four kinds of failures: in imagination, policy, capabilities, and management." The commission made numerous recommendations on how to prevent future attacks, and in 2011 was dismayed that several of its recommendations had yet to be implemented.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.